Cargando…

Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?

BACKGROUND: Renal cell carcinoma (RCC) is the most common renal neoplasm. Cancer tissue is often characterized by altered energy regulation. Fatty acid-binding proteins (FABP) are involved in the intracellular transport of fatty acids (FA). We examined the level of brain-type (B) and liver-type (L)...

Descripción completa

Detalles Bibliográficos
Autores principales: Tölle, Angelika, Jung, Monika, Lein, Michael, Johannsen, Manfred, Miller, Kurt, Moch, Holger, Jung, Klaus, Kristiansen, Glen
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732640/
https://www.ncbi.nlm.nih.gov/pubmed/19622156
http://dx.doi.org/10.1186/1471-2407-9-248
_version_ 1782171065457311744
author Tölle, Angelika
Jung, Monika
Lein, Michael
Johannsen, Manfred
Miller, Kurt
Moch, Holger
Jung, Klaus
Kristiansen, Glen
author_facet Tölle, Angelika
Jung, Monika
Lein, Michael
Johannsen, Manfred
Miller, Kurt
Moch, Holger
Jung, Klaus
Kristiansen, Glen
author_sort Tölle, Angelika
collection PubMed
description BACKGROUND: Renal cell carcinoma (RCC) is the most common renal neoplasm. Cancer tissue is often characterized by altered energy regulation. Fatty acid-binding proteins (FABP) are involved in the intracellular transport of fatty acids (FA). We examined the level of brain-type (B) and liver-type (L) FABP mRNA and the protein expression profiles of both FABPs in renal cell carcinoma. METHODS: Paired tissue samples of cancerous and noncancerous kidney parts were investigated. Quantitative RT-PCR, immunohistochemistry and western blotting were used to determine B- and L-FABP in tumor and normal tissues. The tissue microarray (TMA) contained 272 clinico-pathologically characterized renal cell carcinomas of the clear cell, papillary and chromophobe subtype. SPSS 17.0 was used to apply crosstables (χ(2)-test), correlations and survival analyses. RESULTS: B-FABP mRNA was significantly up-regulated in renal cell carcinoma. In normal tissue B-FABP mRNA was very low or often not detectable. RCC with a high tumor grading (G3 + G4) showed significantly lower B-FABP mRNA compared with those with a low grading (G1 + G2). Western blotting analysis detected B-FABP in 78% of the cases with a very strong band but in the corresponding normal tissue it was weak or not detectable. L-FABP showed an inverse relationship for mRNA quantification and western blotting. A strong B-FABP staining was present in 52% of the tumor tissues contained in the TMA. In normal renal tissue, L-FABP showed a moderate to strong immunoreactivity in proximal tubuli. L-FABP was expressed at lower rates compared with the normal tissues in 30.5% of all tumors. There was no correlation between patient survival times and the staining intensity of both FABPs. CONCLUSION: While B-FABP is over expressed in renal cell carcinoma in comparison to normal renal tissues L-FABP appears to be reduced in tumor tissue. Although the expression behavior was not related to the survival outcome of the RCC patients, it can be assumed that these changes indicate fundamental alterations in the fatty metabolism in the RCC carcinogenesis. Further studies should identify the role of both FABPs in carcinogenesis, progression and with regard to a potential target in RCC.
format Text
id pubmed-2732640
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27326402009-08-27 Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer? Tölle, Angelika Jung, Monika Lein, Michael Johannsen, Manfred Miller, Kurt Moch, Holger Jung, Klaus Kristiansen, Glen BMC Cancer Research Article BACKGROUND: Renal cell carcinoma (RCC) is the most common renal neoplasm. Cancer tissue is often characterized by altered energy regulation. Fatty acid-binding proteins (FABP) are involved in the intracellular transport of fatty acids (FA). We examined the level of brain-type (B) and liver-type (L) FABP mRNA and the protein expression profiles of both FABPs in renal cell carcinoma. METHODS: Paired tissue samples of cancerous and noncancerous kidney parts were investigated. Quantitative RT-PCR, immunohistochemistry and western blotting were used to determine B- and L-FABP in tumor and normal tissues. The tissue microarray (TMA) contained 272 clinico-pathologically characterized renal cell carcinomas of the clear cell, papillary and chromophobe subtype. SPSS 17.0 was used to apply crosstables (χ(2)-test), correlations and survival analyses. RESULTS: B-FABP mRNA was significantly up-regulated in renal cell carcinoma. In normal tissue B-FABP mRNA was very low or often not detectable. RCC with a high tumor grading (G3 + G4) showed significantly lower B-FABP mRNA compared with those with a low grading (G1 + G2). Western blotting analysis detected B-FABP in 78% of the cases with a very strong band but in the corresponding normal tissue it was weak or not detectable. L-FABP showed an inverse relationship for mRNA quantification and western blotting. A strong B-FABP staining was present in 52% of the tumor tissues contained in the TMA. In normal renal tissue, L-FABP showed a moderate to strong immunoreactivity in proximal tubuli. L-FABP was expressed at lower rates compared with the normal tissues in 30.5% of all tumors. There was no correlation between patient survival times and the staining intensity of both FABPs. CONCLUSION: While B-FABP is over expressed in renal cell carcinoma in comparison to normal renal tissues L-FABP appears to be reduced in tumor tissue. Although the expression behavior was not related to the survival outcome of the RCC patients, it can be assumed that these changes indicate fundamental alterations in the fatty metabolism in the RCC carcinogenesis. Further studies should identify the role of both FABPs in carcinogenesis, progression and with regard to a potential target in RCC. BioMed Central 2009-07-21 /pmc/articles/PMC2732640/ /pubmed/19622156 http://dx.doi.org/10.1186/1471-2407-9-248 Text en Copyright ©2009 Tölle et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Tölle, Angelika
Jung, Monika
Lein, Michael
Johannsen, Manfred
Miller, Kurt
Moch, Holger
Jung, Klaus
Kristiansen, Glen
Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?
title Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?
title_full Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?
title_fullStr Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?
title_full_unstemmed Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?
title_short Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?
title_sort brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732640/
https://www.ncbi.nlm.nih.gov/pubmed/19622156
http://dx.doi.org/10.1186/1471-2407-9-248
work_keys_str_mv AT tolleangelika braintypeandlivertypefattyacidbindingproteinsnewtumormarkersforrenalcancer
AT jungmonika braintypeandlivertypefattyacidbindingproteinsnewtumormarkersforrenalcancer
AT leinmichael braintypeandlivertypefattyacidbindingproteinsnewtumormarkersforrenalcancer
AT johannsenmanfred braintypeandlivertypefattyacidbindingproteinsnewtumormarkersforrenalcancer
AT millerkurt braintypeandlivertypefattyacidbindingproteinsnewtumormarkersforrenalcancer
AT mochholger braintypeandlivertypefattyacidbindingproteinsnewtumormarkersforrenalcancer
AT jungklaus braintypeandlivertypefattyacidbindingproteinsnewtumormarkersforrenalcancer
AT kristiansenglen braintypeandlivertypefattyacidbindingproteinsnewtumormarkersforrenalcancer